Skip to content

A Study to See Whether Saraswat Choorna and Yoga Can Help Adult Smokers Quit Smoking

To evaluate the Efficacy of Saraswat Choorna and Yoga Intervention in Smoking Cessation: A Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099974
Enrollment
40
Registered
2025-12-31
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

RGGPG Ayurvedic Collage and Hopital Paprola District Kangra
Lead Sponsor
Prof Dr Vijay Chaudhary
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged between 18 and 60 years Both male and female participants Current smokers defined by smoking at least 100 cigarettes in their lifetime and smoking in the past 7 days Participants willing to provide written informed consent and adhere to the study protocol, including attending yoga sessions and following prescribed interventions Stable Health Condition Participants with no significant acute illness or severe comorbidities that could interfere with the study intervention Participants with stable mental health without active psychiatric conditions psychosis or severe depression that could interfere with the study protocol

Exclusion criteria

Exclusion criteria: Age Limitations Individuals younger than 18 years or older than 60 years Non-Smokers and Former Smokers Individuals classified as never smokers or former smokers abstinent for at least 30 days Medical Conditions Severe cardiovascular diseases eg recent myocardial infarction, unstable angina Severe respiratory conditions eg chronic obstructive pulmonary disease severe asthma Uncontrolled hypertension diabetes mellitus Severe gastrointestinal disorders eg active peptic ulcer Substance Abuse Current alcohol or drug dependence excluding nicotine History of substance abuse within the past 12 months Psychiatric Conditions Severe depression, psychosis, or bipolar disorder Current use of antipsychotic medications or mood stabilizers Pregnancy and Lactation Pregnant or breastfeeding women Women planning to conceive during the study period Yoga or Exercise Contraindications Musculoskeletal disorders limiting physical activity Neurological conditions affecting balance or coordination Allergy or Sensitivity Known allergy or intolerance to Saraswat Choorna or its ingredients Participation in other trials participation in any other smoking cessation program or clinical trial within the past 3 months Non Compliance Inability to follow the study protocol or attend regular sessions Lack of consent or withdrawal from the study at any point.

Design outcomes

Primary

MeasureTime frame
7 Day Point Prevalence Abstinence 7 PPA Appendix 2 Smoking abstinence will be confirmed using rapid test kits for cotinine at the end of the intervention Day 30 Participants will be considered abstinent if they report no smoking in the past 7 days and have a negative cotinine test resultTimepoint: At baseline and on Day 30

Secondary

MeasureTime frame
Psychological Health Changes in psychological health will be measured using the DASS-21 Depression Anxiety and Stress ScaleTimepoint: At baseline and on Day 30;Nicotine Dependence Changes in nicotine dependence using Fagerstrom Test for Nicotine DependenceTimepoint: At baseline and on day 30;Smoking Dependence Changes in Smoking Dependence will be assessed using Brief WISDM Winconsin Inventory of Smoking Dependence MotivesTimepoint: At baseline and on day 30;Smoking Temptation Changes in smoking temptation will be evaluated using Smoking temptation ScaleTimepoint: At baseline and on day 30

Countries

India

Contacts

Public ContactProf Dr Vijay Chaudhary

RGGPG Ayurvedic Collage and Hospital Paprola ,District Kangra, Himachal Pradesh

drvijaychaudhary@gmail.com9418130228

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026